Yazar "Kazaz, Ilke Onur" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group
    (Wiley-Hindawi, 2021) Cinar, Onder; Turunc, Tahsin; Kazaz, Ilke Onur; Yildirim, Omer; Deliktas, Hasan; Cihan, Ahmet; Gudeloglu, Ahmet
    Aims of the study The aim of this study was to investigate the impact of testosterone deficiency on cognitive functions in metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). Methods In this multicentric prospective study, 65 metastatic prostate cancer patients were evaluated. Demographic and clinical data were recorded. Cognitive functions were assessed using the Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test-Revised, and the Trail Making Test. Depressive symptoms were assessed using the Beck Depression Inventory. Cognitive functions and depressive symptoms were recorded before the androgen deprivation therapy and at the 3- and 6-month follow-ups. Results At the basal cognitive assessment, the mean Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test-Revised scores were 25.84 +/- 17.54, 32.68 +/- 10.60, and 17.63 +/- 11.23, respectively, and the mean time for the Trail Making Test was 221.56 +/- 92.44 seconds, and were similar at the 3-month, and 6-month controls (P > .05). The mean pretreatment, third and sixth month testosterone levels were 381.40 +/- 157.53 ng/dL, 21.61 +/- 9.09 ng/dL and 12.25 +/- 6.45 ng/dL (P < .05), and the total PSA levels were 46.46 +/- 37.83 ng/mL, 1.41 +/- 3.31 ng/mL and 0.08 +/- 0.14 ng/mL (P < .05), respectively. Conclusion The ADT in patients with metastatic prostate cancer does not affect patients' cognitive functions and depressive symptoms. However, further prospective randomised studies with higher cohorts and longer follow-up periods are needed.
  • Küçük Resim Yok
    Öğe
    Prevalence of Poor Sleep Quality and Its Determinants Among Men Suffering from Erectile Dysfunction
    (Galenos Publ House, 2023) Cihan, Ahmet; Kazaz, Ilke Onur; Duran, Mesut Berkan; Yildrim, Omer; Baser, Aykut; Guel, Uemit; Hasirci, Eray
    Objective: Recent findings implicate a higher prevalence of erectile dysfunction (ED) among men with sleep disorders. We investigated sleep quality among men with ED. Materials and Methods: A prospective study was conducted at 12 different andrology outpatient clinics among men with complaints of insufficient erections. The subjective quality of sleep was measured using the Pittsburgh Sleep Quality Inventory. Erectile function and its dimensions were measured using the International Index of Erectile Function (IIEF) questionnaire. The age-adjusted Charlson comorbidity index and Beck Depression Inventory were used to evaluate interrelations with comorbid disease severity and depression of the subjects consecutively in the study. Results: Among 431 eligible men, the median age of the participants and their erectile function scores in the IIEF were 51 [interquartile range (IQR)=43-59] and 16 (IQR=11-19), respectively. Poor sleep was observed in 192 of 431 (44.5%) subjects. Multivariable analysis revealed that younger age [odds ratio (OR)=0.95, p=0.01], lower body mass (OR=0.86, p=0.01), lower serum high-density lipoprotein cholesterol (OR=0.95, p=0.02), and higher severity of depression (0R=2.1, p=0.0001) were predictors of poor sleep quality among men with ED. Conclusion: Nearly half of the men with ED also suffer from poor sleep. Younger age, lean body mass, and severe depression were the main predictors of poor sleep quality among ED sufferers.